Development of pharmacological strategies for mitochondrial disorders
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Mitochondrial diseases are an unusually genetically and phenotypically heterogeneous group of disorders, which are extremely challenging to treat. Currently, apart from supportive therapy, there are no effective treatments for the vast majority of mitochondrial diseases. Huge scientific effort, however, is being put into understanding the mechanisms underlying mitochondrial disease pathology and developing potential treatments. To date, a variety of treatments have been evaluated by randomized clinical trials, but unfortunately, none of these has delivered breakthrough results. Increased understanding of mitochondrial pathways and the development of many animal models, some of which are accurate phenocopies of human diseases, are facilitating the discovery and evaluation of novel prospective treatments. Targeting reactive oxygen species has been a treatment of interest for many years; however, only in recent years has it been possible to direct antioxidant delivery specifically into the mitochondria. Increasing mitochondrial biogenesis, whether by pharmacological approaches, dietary manipulation or exercise therapy, is also currently an active area of research. Modulating mitochondrial dynamics and mitophagy and the mitochondrial membrane lipid milieu have also emerged as possible treatment strategies. Recent technological advances in gene therapy, including allotopic and transkingdom gene expression and mitochondrially targeted transcription activator‐like nucleases, have led to promising results in cell and animal models of mitochondrial diseases, but most of these techniques are still far from clinical application. Linked Articles: This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondria: In Sickness and in Health
Nunnari, J., & Suomalainen, A. (2012) · Cell · doi:10.1016/j.cell.2012.02.035 · Cited by 3,479
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300 · cited 2×
“, 2007) since AMPK increases NAD levels that increase SIRT1 activity (Beher et al., 2009; Canto et al., 2009), which up-regulates PGC-1α as discussed above.”
BackgroundAMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
Jäger, S., Handschin, C., St.-Pierre, J., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705070104 · Cited by 2,491
Mitochondrial transcription factor A is necessary for mtDNA maintance and embryogenesis in mice
Larsson, N.-G., Wang, J., Wilhelmsson, H., Oldfors, A., Rustin, P., Lewandoski, M., Barsh, G. S., & Clayton, D. A. (1998) · Nature Genetics · doi:10.1038/ng0398-231 · Cited by 1,594
Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A
Züchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E. L., Zappia, M., Nelis, E., Patitucci, A., Senderek, J., et al. (2004) · Nature Genetics · doi:10.1038/ng1341 · Cited by 1,572
Alexander, C., Votruba, M., Pesch, U. E. A., Thiselton, D. L., Mayer, S., Moore, A., Rodriguez, M., Kellner, U., Leo-Kottler, B., Auburger, G., et al. (2000) · Nature Genetics · doi:10.1038/79944 · Cited by 1,330
Cassidy-Stone, A., Chipuk, J. E., Ingerman, E., Song, C., Yoo, C., Kuwana, T., Kurth, M. J., Shaw, J. T., Hinshaw, J. E., Green, D. R., et al. (2008) · Developmental Cell · doi:10.1016/j.devcel.2007.11.019 · Cited by 1,200
Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
The role of mitochondria in aging
Bratic, A., & Larsson, N.-G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64125 · Cited by 1,087 · cited 2×
“Recently, the term mitochondrial disorders has become very popular, finding its place in reference to many metabolic diseases, Alzheimer’s disease, Parkinson’s disease, type 2 diabetes and aging (Patti and Corvera, 2010; Coskun et al., 2012; Bratic and Larsson, 2013).”
BackgroundAconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia
Rötig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A., & Rustin, P. (1997) · Nature Genetics · doi:10.1038/ng1097-215 · Cited by 991
A Lethal Defect of Mitochondrial and Peroxisomal Fission
Waterham, H. R., Koster, J., van Roermund, C. W. T., Mooyer, P. A. W., Wanders, R. J. A., & Leonard, J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064436 · Cited by 749 · cited 3×
“, 2004), and impaired mitochondrial fission caused by mutations in DRP1 and MFF (Waterham et al., 2007; Shamseldin et al., 2012).”
BackgroundA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578 · cited 1×
“A study in LHON did not show a significant change in the primary outcome measure (best eye recovery) but there was a suggestion of improvement in a subgroup (Klopstock et al., 2011).”
BackgroundThe role of mitochondria in the pathogenesis of type 2 diabetes
Patti, M.-E., & Corvera, S. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0027 · Cited by 551
Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs
Bacman, S. R., Williams, S. L., Pinto, M., Peralta, S., & Moraes, C. T. (2013) · Nature Medicine · doi:10.1038/nm.3261 · Cited by 432
Suomalainen, A., Elo, J. M., Pietiläinen, K. H., Hakonen, A. H., Sevastianova, K., Korpela, M., Isohanni, P., Marjavaara, S. K., Tyni, T., Kiuru-Enari, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70155-7 · Cited by 427 · cited 2×
“In Deletor mice, FGF21 levels correlated with increased COX-negative fibres (Tyynismaa et al., 2010), and subsequently, FGF21 was found to be elevated in patients with mitochondrial disorders with skeletal muscle involvement (Suomalainen et al., 2011).”
BackgroundResveratrol is not a direct activator of SIRT1 enzyme activity
Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S., Atangan, L., & Wang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00901.x · Cited by 426 · cited 2×
“, 2007) since AMPK increases NAD levels that increase SIRT1 activity (Beher et al., 2009; Canto et al., 2009), which up-regulates PGC-1α as discussed above.”
BackgroundPharmacological approaches to restore mitochondrial function
Andreux, P. A., Houtkooper, R. H., & Auwerx, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4023 · Cited by 383 · cited 7×
“1808 British Journal of Pharmacology (2014) 171 1798–1817 Targeting mitochondrial dynamics and mitophagy The increasing recognition of mitochondria as highly dynamic organelles has led to a new focus for targeting novel therapeutic strategies (Andreux et al., 2013).”
BackgroundInfluentialTyynismaa, H., Mjosund, K. P., Wanrooij, S., Lappalainen, I., Ylikallio, E., Jalanko, A., Spelbrink, J. N., Paetau, A., & Suomalainen, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505551102 · Cited by 342
The Protein Import Machinery of Mitochondria
Wiedemann, N., Frazier, A. E., & Pfanner, N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400003200 · Cited by 336
Mitochondrial myopathy induces a starvation-like response
Tyynismaa, H., Carroll, C. J., Raimundo, N., Ahola-Erkkilä, S., Wenz, T., Ruhanen, H., Guse, K., Hemminki, A., Peltola-Mjøsund, K. E., Tulkki, V., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq310 · Cited by 300
Mitochondrial DNA polymerase gamma is essential for mammalian embryogenesis
Hance, N., Ekstrand, M. I., & Trifunovic, A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi184 · Cited by 272
Mitochondrial disorders: prevalence, myths and advances
Thorburn, D. R. (2004) · Journal of Inherited Metabolic Disease · doi:10.1023/b:boli.0000031098.41409.55 · Cited by 258 · cited 1×
“Mitochondrial diseases have a prevalence of approximately 1 in 5000 (Thorburn, 2004).”
BackgroundBeneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
Taivassalo, T., Gardner, J. L., Taylor, R. W., Schaefer, A. M., Newman, J., Barron, M. J., Haller, R. G., & Turnbull, D. M. (2006) · Brain · doi:10.1093/brain/awl282 · Cited by 220
Shamseldin, H. E., Alshammari, M., Al-Sheddi, T., Salih, M. A., Alkhalidi, H., Kentab, A., Repetto, G. M., Hashem, M., & Alkuraya, F. S. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-100836 · Cited by 182
Gene shifting: a novel therapy for mitochondrial myopathy
Taivassalo, T. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.6.1047 · Cited by 160 · cited 2×
“Exercise therapy Exercise therapy was initially explored as a method for ‘heteroplasmy shifting’, that is, to reduce the relative proportion of mutant to wild-type mtDNA in patients with heteroplasmic mtDNA deletions and point mutations (Taivassalo et al., 1999).”
MethodLamari, F., Mochel, F., Sedel, F., & Saudubray, J. M. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9509-7 · Cited by 104 · cited 2×
“Recently four other disorders have been linked to abnormalities of mitochondrial phospholipid biosynthesis or remodelling (Lamari et al., 2013): rhabdomyolysis associated with mutations in LPIN1 (Zeharia et al.”
BackgroundKornblum, C., Schröder, R., Müller, K., Vorgerd, M., Eggers, J., Bogdanow, M., Papassotiropoulos, A., Fabian, K., Klockgether, T., & Zange, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00970.x · Cited by 65
Cited by
Mitochondrial medicine in the omics era
Rahman, J., & Rahman, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30727-x · Cited by 283
Self-citationCharlton, N. C., Mastyugin, M., Török, B., & Török, M. (2023) · Molecules · doi:10.3390/molecules28031057 · Cited by 258
Metabolism, Metabolomics, and Inflammation in Posttraumatic Stress Disorder
Mellon, S. H., Gautam, A., Hammamieh, R., Jett, M., & Wolkowitz, O. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.02.007 · Cited by 184
Mitochondrial Dysfunction in Skeletal Muscle Pathologies
Abrigo, J., Simon, F., Cabrera, D., Vilos, C., & Cabello-Verrugio, C. (2019) · Current Protein & Peptide Science · doi:10.2174/1389203720666190402100902 · Cited by 88
Neubauer, M., Zhu, Z., Penka, M., Helmschrott, C., Wagener, N., & Wagener, J. (2015) · Molecular Microbiology · doi:10.1111/mmi.13167 · Cited by 76
“As a result, the search for more chemical effectors of mitochondrial dynamics is on (Lackner and Nunnari, 2010; Andreux et al., 2013; Itoh et al., 2013; Kanabus et al., 2014).”
Background
Metadata
- Authors
- Kanabus, M., Heales, S. J., & Rahman, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-03-28
- Volume
- 171
- Issue
- 8
- Pages
- 1798-1817
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1655824331
- Cited by
- 78
- References
- 28
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.